Drug intelligence / Profile preview

TAVT-119

Development stage: Unknown
Lead developer: Tavanta Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

TAVT-119 is a topical gel formulation of amlodipine besylate, a dihydropyridine calcium channel blocker, currently under development by Tavanta Therapeutics for the treatment of chronic anal fissures. The drug is applied perianally to exert a local effect by relaxing the smooth muscle of the internal anal sphincter. This relaxation reduces intra-anal pressure and improves local blood flow, which are critical factors in promoting the healing of anal fissures. TAVT-119 is designed to minimize systemic absorption, thereby reducing the risk of systemic side effects typically associated with oral calcium channel blockers, such as hypotension or peripheral edema. It is currently being evaluated in Phase 2 clinical trials.

Other names: amlodipine besylate gel

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on TAVT-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAVT-119.